Skip to main content

Table 3 Qualitative summary of efficacy outcomes

From: Spinal cord stimulation in the treatment of refractory angina: systematic review and meta-analysis of randomised controlled trials

A. SCS vs. active comparator studies
Trial Name/author Outcome Within group difference SCS Within group difference Control Between group difference SCS vs. control
ESBY 1998 (vs CABG) Nitrate drug usage 6-mo + 6-mo + 6-mo =
   2-yr + 2-yr + 2-yr =
  Exercise capacity 6-mo = 6-mo + 6-mo --
  Total mortality NR NR 6-mo +
   NR NR 2-yr =
   NR NR 5-yr =
  Non fatal morbidity NR NR 6-mo =
  Ischemic burden 6-mo = 6-mo = 6-mo =
  HRQoL (QLQ-AP & NHP) 6-mo + 6-mo + 6-mo =
   2-yr + 2-yr + 2-yr =
   6-mo + 6-mo+ 6-mo =
  Angina    
SpiRiT 2006* (vs PMR) Exercise capacity 3-mo + 3-mo = 3-mo =
   12-mo = 12-mo = 12-mo =
  CCS class 3-mo + 3-mo + 3-mo +
   12-mo + 12-mo + 12-mo =
  HRQoL (SF-36 & 3-mo + 3-mo + 3-mo =
  SAQ)* 12-mo + 12-mo + 12-mo =
B. SCS vs no SCS/SCS OFF studies
Trial Name/author Outcome Within group difference SCS Within group difference Control Between group difference SCS vs. control
DeJongste 1994 Exercise capacity + = +
  Nitrate drug usage + = +
  HRQoL (ADL score) + = +
Hautvast 1998 Exercise capacity + = +
  Nitrate drug usage + = =
  HRQoL (LASA) + = =
  Ischemic burden + = =
Jessurun 1999 Exercise capacity NR NR =
  Ischemic burden NR NR =
  Nitrate drug usage NR NR =
DiPede 2001 Eddicks 2007 Ischemic burden NR NR =
  Exercise capacity NR NR +
  Nitrate drug usage NR NR +
  HRQoL (SAQ) NR NR +/=
  (EQ-5D) NR NR +
  CCS class NR NR +
  Angina attacks NR NR +
  1. *additional data supplied by authors
  2. HRQOL: health-related quality of life; ADL: activities of daily living score; SF-35: Short-form 36 questionnaire; NHP: Nottingham Health Profile; QLQ-AP: Quality of Life Questionnaire – Angina Pectoris; SAQ: Seattle Angina Questionnaire; SAS: Social Activity Scale; LASA: Linear Analogue Self Assessment; VAS – visual analogue scale; 6-MWT: 6 minute walk test; NR: not reported
  3. +: within group – improvement (P ≤ 0.05) in outcome with SCS or control at follow up compared to baseline; between group – superior (P ≤ 0.05) outcome at follow up with SCS compared to control
  4. -: within group – worsening (P ≤ 0.05) in outcome with SCS or control at follow up compared to baseline; between group – superior (P ≤ 0.05) outcome at follow up with control compared to SCS
  5. =: within group – no change (P > 0.05) in outcome with SCS or control at follow up compared to baseline; between group – no difference (P > 0.05) outcome at follow up of SCS compared to control